Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
17.05 USD | -0.47% |
|
-9.05% | +14.03% |
04/06 | Wedbush Adjusts Price Target on NovoCure to $24 From $21, Maintains Neutral Rating | MT |
03/06 | Novocure Announces the Presentation of Clinical Data from the Phase 3 Metis Trial | CI |
This article is reserved for members
Already a member?
Log InNot a member ?
Free registration![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+14.03% | 1.84B | |
+75.69% | 12.57B | |
-29.73% | 6.98B | |
-0.69% | 6.69B | |
+9.17% | 5.18B | |
+15.44% | 4.18B | |
-23.98% | 3.81B | |
-23.75% | 2.8B | |
-1.49% | 2B | |
+1.71% | 1.83B |
- Stock Market
- Equities
- NVCR Stock
- News NovoCure Limited
- NovoCure Says US FDA Accepts Its Premarket Approval Application for Tumor Treating Fields in Lung Cancer; Shares Rise